Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Dyne Therapeutics to Present New Preclinical Data
Dyne Therapeutics to Present New Preclinical Data
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Radiopharm Theranostics Reports Preclinical
Radiopharm Theranostics Reports Preclinical
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Darolutamide Receives FDA Approval for mCSPC
Darolutamide Receives FDA Approval for mCSPC
The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.
Four States Ask F.D.A. to Lift Special Restrictions on Abortion Pill
Four States Ask F.D.A. to Lift Special Restrictions on Abortion Pill
The states consider it a move to force the F.D.A. to review and acknowledge extensive research showing the pill’s safety. Mifepristone, which blocks a hormone necessary for pregnancy to develop, was...
FDA phasing out animal testing in preclinical safety studies
FDA phasing out animal testing in preclinical safety studies
The Food and Drug Administration (FDA) said it will reduce or replace its animal testing requirement for “more effective, human-relevant methods,” such as artificial intelligence (AI&#...
Alvotech and Advanz to commercialise biosimilars in Europe
Alvotech and Advanz to commercialise biosimilars in Europe
Alvotech and UK-based Advanz Pharma have broadened their commercial collaboration with an agreement to include three additional biosimilar candidates for commercialisation in Europe.
UCLA Study Finds SSRIs Enhance T Cell Activity and Reduce Tumor Growth in Preclinical Cancer Models
UCLA Study Finds SSRIs Enhance T Cell Activity and Reduce Tumor Growth in Preclinical Cancer Models
A recent study conducted by researchers at UCLA has identified a potential link between commonly used antidepressants and enhanced cancer-fighting capabilities of the immune system.
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal an...
Sevabertinib Given FDA Priority Review for HER2+ NSCLC
Sevabertinib Given FDA Priority Review for HER2+ NSCLC
The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer. The FDA gave sevabertinib breakthrough therapy designation for HE...
FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease
FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease
The FDA has granted fast track designation to TEV-53408 (Teva Pharmaceutical Industries, Ltd), an investigational anti-IL-15 antibody designed for the treatment of individuals with celiac dise...
EMA validates Soleno’s
EMA validates Soleno’s
EMA validates Soleno’s application for Prader-Willi syndrome treatment
Quadria's third fund
Quadria's third fund
Quadria's third fund nets $1 billion, to deploy 60% in India
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand